Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Vectibix (panitumumab by Quarter
Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide volume growth YoY (%) (%)
Amgen Vectibix (panitumumab: 11.0% in Q1 2026.
Latest, Q1 2026
11.0%
Period ended Mar 31, 2026
Change on a year earlier
–
History
8 quarters
Since Q2 2021
Sources
8
Documents cited below
Where the Q1 2026 figure comes from
“Vectibix ® (panitumumab) sales increased 7% year-over-year to $287 million in the first quarter, driven by 11% volume growth, partially offset by lower inventory levels.”
Source: Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Reported in Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide volume growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | 11.0% | – | Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 23.0% | +27.0 pts | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| Q4 2024 | Dec 31, 2024 | -4.0% | – | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| Q3 2023 | Sep 30, 2023 | 4.0% | – | Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 20.0% | – | Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗ |
| Q1 2023 | Mar 31, 2023 | 15.0% | – | Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 8.0% | – | Form 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 20.0% | – | Form 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗ |
Cite this data
StockData. (2026). Amgen Vectibix (panitumumab (%), quarterly Q2 2021–Q1 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-vectibix-vol
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.